Ortivus AB completes sale of its holding in H&E Solutions AB and realises a profit
Idag, 08:45
Ortivus AB today announces that it has completed the sale of its entire shareholding in the technology company H&E Solutions AB (Evam) for a purchase price of SEK 5.2 million. The transaction results in a realised profit and strengthens Ortivus’ liquidity, while the successful collaboration relating to MobiMed enRoute continues unchanged.
In January 2023, Ortivus acquired approximately 10 per cent of the shares in H&E Solutions AB for SEK 4.0 million. Since then, the companies have maintained a close and successful collaboration, particularly in the development and integration of MobiMed enRoute – a navigation and case management solution that forms a module within the Ortivus MobiMed platform.
Ortivus has now chosen to sell its shareholding in H&E Solutions AB for SEK 5.2 million. The decision is based on the fact that H&E Solutions has brought in new, well-capitalised owners, creating a favourable opportunity for Ortivus to realise a profit on its investment and further strengthen the company’s liquidity.
“We are selling our shares in H&E Solutions as a strategic decision that strengthens our cash position and enables us to realise a solid return. It is important to emphasise that our close collaboration regarding MobiMed enRoute will continue as before. This is a highly valuable solution for our customers, and we look forward to continuing to deliver market-leading solutions for pre-hospital care together,” says Gustaf Nordenhök, CEO of Ortivus.
The divestment does not affect the operational collaboration between the companies or the functionality of the products offered to Ortivus’ customers.
Contacts
For further information, please contact
Gustaf Nordenhök, CEO
Phone +46 8 446 45 00
About Ortivus
Ortivus has extensive experience in mobile communication solutions and a unique understanding of clinical healthcare. We develop interactive and user-friendly solutions that support diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating our solutions with electronic health records, dispatch systems, and national registries, we ensure fast and secure information management, a crucial factor in creating a more integrated care process.
Our solutions save valuable time for healthcare professionals, optimise resource use, and reduce the need for avoidable patient transports, resulting in more cost-effective and patient-centred care. With our combination of advanced technology and deep clinical expertise, we support our customers in meeting the healthcare challenges of today and tomorrow.
Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market and the company’s Certified Adviser is FNCA Sweden AB.
Read more about our solutions at www.ortivus.com
This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-05-04 08:45 CEST.
Attachments
Ortivus AB completes sale of its holding in H&E Solutions AB and realises a profit
Ortivus AB completes sale of its holding in H&E Solutions AB and realises a profit
Idag, 08:45
Ortivus AB today announces that it has completed the sale of its entire shareholding in the technology company H&E Solutions AB (Evam) for a purchase price of SEK 5.2 million. The transaction results in a realised profit and strengthens Ortivus’ liquidity, while the successful collaboration relating to MobiMed enRoute continues unchanged.
In January 2023, Ortivus acquired approximately 10 per cent of the shares in H&E Solutions AB for SEK 4.0 million. Since then, the companies have maintained a close and successful collaboration, particularly in the development and integration of MobiMed enRoute – a navigation and case management solution that forms a module within the Ortivus MobiMed platform.
Ortivus has now chosen to sell its shareholding in H&E Solutions AB for SEK 5.2 million. The decision is based on the fact that H&E Solutions has brought in new, well-capitalised owners, creating a favourable opportunity for Ortivus to realise a profit on its investment and further strengthen the company’s liquidity.
“We are selling our shares in H&E Solutions as a strategic decision that strengthens our cash position and enables us to realise a solid return. It is important to emphasise that our close collaboration regarding MobiMed enRoute will continue as before. This is a highly valuable solution for our customers, and we look forward to continuing to deliver market-leading solutions for pre-hospital care together,” says Gustaf Nordenhök, CEO of Ortivus.
The divestment does not affect the operational collaboration between the companies or the functionality of the products offered to Ortivus’ customers.
Contacts
For further information, please contact
Gustaf Nordenhök, CEO
Phone +46 8 446 45 00
About Ortivus
Ortivus has extensive experience in mobile communication solutions and a unique understanding of clinical healthcare. We develop interactive and user-friendly solutions that support diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating our solutions with electronic health records, dispatch systems, and national registries, we ensure fast and secure information management, a crucial factor in creating a more integrated care process.
Our solutions save valuable time for healthcare professionals, optimise resource use, and reduce the need for avoidable patient transports, resulting in more cost-effective and patient-centred care. With our combination of advanced technology and deep clinical expertise, we support our customers in meeting the healthcare challenges of today and tomorrow.
Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market and the company’s Certified Adviser is FNCA Sweden AB.
Read more about our solutions at www.ortivus.com
This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-05-04 08:45 CEST.
Attachments
Ortivus AB completes sale of its holding in H&E Solutions AB and realises a profit
Analys
Analys
Marknadsöversikt
1 DAG %
Senast
1 mån
